2595
vs
H
Hang Seng (Hong Kong)
2595
Over the past 12 months, GenFleet Therapeutics (Shanghai) Inc has underperformed Hang Seng (Hong Kong), delivering a return of -33% compared to the Hang Seng (Hong Kong)'s +5% growth.
Stocks Performance
2595 vs Hang Seng (Hong Kong)
Performance Gap
2595 vs Hang Seng (Hong Kong)
Performance By Year
2595 vs Hang Seng (Hong Kong)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
GenFleet Therapeutics (Shanghai) Inc
Glance View
Genfleet Therapeutics (Shanghai), Inc. operates as a commercial-stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2025-09-19. The firm provides effective new treatment solutions for tumors, autoimmune and inflammatory diseases, covering target discovery, molecular discovery and evaluation, translational science and clinical development, as well as key chemistry manufacturing and controls aspects including formulation research, process development and quality analysis. The firm is mainly engaged in the development of new molecular entities, novel molecular modalities, investigation of molecular process routes and quality standards, and exploration of differentiated clinical development strategies and paths. The firm mainly primarily operates in the domestic and international markets.
